Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Deuterium-Altered Ruxolitinib for Alopecia Areata

Key clinical point: Deuterated ruxolitinib slowed hair loss and increased hair growth in patients with moderate-severe alopecia areata.

Major finding: The 8 mg twice daily dose decreased hair loss by at least 50% in 47% of patients.

Study details: The dose-finding, placebo-controlled study enrolled 101 patients with moderate to severe alopecia areata.

Disclosures: Dr. Cassella is the chief development officer of Concert Pharmaceuticals, the company developing the molecule.

Citation:

Cassella, James et al. AAD 2019, S034, late breaking clinical trials.